Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus XENON XE 133 V S S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus XENON XE 133 V S S.
FLUDEOXYGLUCOSE F18 vs XENON XE 133-V.S.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
Xenon Xe-133 is a radioactive gas that emits beta and gamma radiation. It distributes to the lungs and is used for ventilation-perfusion imaging. Its mechanism is based on regional distribution in the lungs, reflecting ventilation. It does not have pharmacological activity.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
5-10 mCi (185-370 MBq) inhaled as a single dose for pulmonary ventilation imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Terminal elimination half-life of approximately 3.5 minutes, corresponding to rapid washout from lungs following cessation of inhalation.
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Eliminated almost entirely via exhalation through the lungs (>95%); negligible renal or biliary/fecal excretion.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical